Fast Five Quiz: Chronic Myelogenous Leukemia Management

Emmanuel C. Besa, MD


September 21, 2022

On the basis of follow-up data from the BFORE, DASISION, and ENESTnd trials, a second-generation TKI (bosutinib, dasatinib, or nilotinib) is the preferred treatment option for patients with intermediate- or high-risk chronic phase CML. According to NCCN guidelines, the first-generation TKI, imatinib, is another recommended (but not preferred) option.

Learn more about treatment protocols for intermediate- or high-risk CML.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.